The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety results of a multi-center phase I study of utidelone capsule, a novel oral microtubule inhibitor, in advanced solid tumor patients.
 
Judy Wang
Consulting or Advisory Role - Fusion Pharmaceuticals
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Alterome Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Biostar (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Centessa Pharmaceuticals (Inst); Circle Pharma (Inst); Compass Therapeutics (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); DualityBio (Inst); Edgewood Oncology (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Genmab (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kumquat (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo/Lilly (Inst); LSK Global (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MBQ Pharma (Inst); Medikine (Inst); MediLink Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); Qilu Puget Sound Biotherapeutics (Inst); Quanta Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Lab (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - NGM Biopharmaceuticals
 
Brian Van Tine
Leadership - Polaris
Honoraria - Beijing Biostar Pharmaceuticals Co., Ltd.; Oncology Education; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; Adaptimmune; Advenchen Laboratories; Boxer Capital LLC; Crisper Therapeutics; Daiihi Sankyo; Deciphera; Galapagos NV; Hinge Bio; Kronos Bio, Inc.; Putnam Associates; Salarius Pharmaceuticals, INc.; Syneos Health
Research Funding - Polaris
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Kura Oncology; Mitsubishi Tanabe Pharma; Nurix; shivanka Research
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)
 
Diana Hanna
Consulting or Advisory Role - AstraZeneca
Research Funding - Agenus (Inst); BeiGene (Inst); Dragonfly Therapeutics (Inst); Dragonfly Therapeutics (Inst); Geistlich Pharma (Inst); Genentech/Roche (Inst); Indaptus Therapeutics (Inst); Phanes Therapeutics (Inst); SpringWorks Therapeutics (Inst); Toray Industries (Inst); Xilio Therapeutics (Inst); Zymeworks (Inst)
 
Li Tang
No Relationships to Disclose
 
Jin Guan
No Relationships to Disclose
 
Jacob Thomas
Consulting or Advisory Role - Conjupro Biotherapeutics; Kura Oncology